Abstract
Since the identification of vascular endothelial growth factor (VEGF) as a mediator of retinal and choroidal neovascularization,1,2 anti-VEGF agents have been universally adopted as the first-line treatment for several ocular conditions.3-8 Pegaptanib (an anti-VEGF RNA aptamer) was approved for neovascular age-related macular degeneration (AMD) in 2004.9,10 Approval of bevacizumab (human anti-VEGF) in combination with chemotherapy for colon cancer came in 2004,11-13 with evidence for the use of bevacizumab for neovascular AMD emerging soon after.14,15 This approval coincided with the development of ranibizumab, an anti-angiogenic monoclonal antibody fragment.16 Ranibizumab has been shown to be highly effective for neovascular AMD,17,18 macular edema after branch retinal vein occlusion19,20 and central retinal vein occlusion,21,22 and diabetic macular edema.23,24 Ranibizumab was approved by the US Food and Drug Administration (FDA) for multiple ocular conditions, while use of bevacizumab in ophthalmology remains off-label. Aflibercept, a “VEGF-trap” (an agent that blocks the action of VEGF)25 approved by the FDA in 2011, is likewise effective for AMD,26 macular edema after retinal vein occlusion,27 and diabetic macular edema.28

This publication has 52 references indexed in Scilit: